Search

everythinglearnresearchcommunity

for

Search:↓

Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.

A user discusses using latanoprost, a costly treatment that may extend the hair growth phase and improve hair quality, wondering why it's not more popular. They already use a combination of finasteride and minoxidil and plan to incorporate latanoprost into their routine.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

Tressless GPT is now free and accessible for hair loss advice. Treatments discussed include Minoxidil, finasteride, RU58841, dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

A user is planning to use mesotherapy with 0.025% dutasteride for hair maintenance due to intolerance to finasteride. They seek clinics in Northern Germany, Sweden, or nearby countries for dutasteride scalp injections.

The user is using RU58841 twice daily, dutasteride 0.5mg every two days, dutasteride mesotherapy every three months, and 20mg oral minoxidil daily. Other users suggest this regimen is excessive and recommend adding microneedling and ketoconazole shampoo.

The conversation is about using a topical solution of latanoprost and minoxidil for hair loss, with concerns about side effects due to a history of gynecomastia. The user is considering this treatment instead of finasteride and is seeking experiences from others.

The conversation discusses a topical finasteride therapy with hydrocortisone butyrate, estrone base, and breviline. A user suggests oral finasteride as a superior option.

The user reports progress in hair regrowth using finasteride every other day, topical minoxidil once daily, ketoconazole twice a week, and Vitamin D3 with zinc. They note improvement in temple areas and the appearance of baby hairs.

A new hair loss treatment, KX-826, is being discussed as a stronger and safer alternative to RU58841 and finasteride. Opinions are mixed, with some users skeptical about its effectiveness and others considering it as part of their regimen.

The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

The post discusses the use of latanoprost foam for hair growth, with the user expressing concerns about its efficiency and safety. The user is currently using topical dutasteride, which maintains their hair but doesn't promote regrowth, and is seeking a product that doesn't affect hormone levels.

OP noticed fuller and thicker hair after almost 4 months of using GHK-Cu, a copper-binding peptide, through subcutaneous injections. Some users were skeptical, questioning the authenticity and potential commercial intent behind the post.

The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.

The conversation discusses the link between increased estrogen and autoimmune diseases, with a focus on avoiding soy and milk. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

GT20029 is a potential treatment for androgenetic alopecia, addressing the root cause by targeting androgen receptors, unlike Minoxidil or Finasteride. It is seen as a preventative measure rather than a regrowth agent, with hopes for market release soon.

The conversation discusses using aromatase inhibiting supplements like DIM and Grape Seed extract while on finasteride for hair loss treatment. Users share their experiences and opinions on combining these supplements with finasteride.

Topical Dutasteride is more effective than topical Finasteride for treating AGA in men, with fewer side effects. Mesotherapy with Dutasteride, administered every 3 months, shows promising results for hair regrowth and maintenance without daily routines or significant side effects.

The conversation is about the results of using hormone replacement therapy (HRT) with estrogen and finasteride for hair loss, and switching from finasteride to bicalutamide as an anti-androgen treatment. The user shared before and after photos to discuss the effectiveness of these treatments.

The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.

Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.

A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.

Breezula's phase 2 showed reduced efficacy after 6 months, but phase 3 had positive results, causing confusion about any changes made to the drug. There is frustration over the long timeline for hair loss treatments, with some users expressing more interest in other potential treatments like GT-20029.

A female user with alopecia is researching peptide usage, specifically ghk-cu, for hair loss. Other users shared mixed experiences with copper treatments, noting some success with topical application.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The conversation discusses the safety, tolerability, and efficacy of oral Setipiprant tablets for treating androgenetic alopecia compared to finasteride. It mentions the high cost of Setipiprant on the black market and the trial's end date in September 2017.

A user's father experienced hair regrowth and other health improvements after two IV exosome treatments. The user also had four rounds of exosome therapy, noting significant hair regrowth and relief from headaches, but no change in gray hair.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

User wants to mix finasteride into stemoxydine instead of minoxidil. Seeks stemoxydine brand recommendations for mixing in the UK.

The conversation discusses the potential release of Winlevi in 2019 by Cassiopeia for hair loss treatment. It suggests a regimen combining minoxidil, Winlevi, Nizoral, and possibly dermarolling, with a comment mentioning Breezula as an alternative to finasteride without side effects.